ASCO GU 2023-Renal Cell Carcinoma
Advertisement
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Current categorization of pN1 can be subdivided into pN1 and pN2 based on a threshold hypothesized by researchers.
Researchers assessed TFS outcomes from HCRN GU16-260, investigating nivolumab and salvage nivolumab plus ipilimumab for aRCC.
Updated OS and efficacy results of second-line treatment in patients with mRCC treated in the BIONIKK trial were presented.
A survey shed light on current practice patterns for treatment selection and patient education for individuals with RCC.
Researchers presented the largest retrospective characterization of localized RCC with sarcomatoid dedifferentiation.
Latinx patients with mRCC demonstrated shorter PFS after nivolumab-plus-ipilimumab treatment at a tertiary care center.
A 24-month analysis highlighted OS, PFS, ORR, and best response to avelumab-plus-axitinib treatment in patients with aRCC.
Researchers compared the survival, efficacy, and safety features of second-line treatment regimens for mccRCC.
A research team sought to learn how patients and physicians trade off features of adjuvant RCC treatments.
Tian Zhang, MD, describes the current standard-of care treatment approach for metastatic RCC, including second-line therapy.
Matthew Zibelman, MD, highlights SOC adjuvant therapy for localized RCC and practice-changing potential of novel therapies.
Attendees will learn about different ways of managing renal cell carcinoma at all stages from research to practice.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.